검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | GP (Gemcitabine + cisplatin, Gemcitabine + cisplatin (GP)) XIANG YANQUN·Nasopharyngeal Cancinoma (NPC) ORR 50% |
|---|---|
Overview Program | Gemcitabine + cisplatin (GP) |
Overview Company | XIANG YANQUN |
Overview Modality | ANTIBODY |
Overview Target | Nasopharyngeal Cancinoma (NPC) |
Overview Indication | Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway |
MoA Biomarker | biomarkers, enhanced trial matching, and scalable cohort identification |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials.. The efficacy and safety of rezafungin in invasive candidiasis (IC) and candidaemia was demonstrated in the Phase 2 STRIVE and Phase 3 ReSTORE trials, and an additional cohort of patients in ReSTORE from China (ReSTORE China). This post hoc analysis is the first time tha… |
Clinical Primary efficacy | ORR 50% |
Clinical ORR | 50% |
Clinical Result source | ClinicalTrials.gov NCT00388154 |
Clinical Data Tier / Score | A · 60 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | GP (Gemcitabine + cisplatin, Gemcitabine + cisplatin (GP)) XIANG YANQUN·Nasopharyngeal Cancinoma (NPC) ORR 50% |
|---|---|
Overview Program | Gemcitabine + cisplatin (GP) |
Overview Company | XIANG YANQUN |
Overview Modality | ANTIBODY |
Overview Target | Nasopharyngeal Cancinoma (NPC) |
Overview Indication | Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway |
MoA Biomarker | biomarkers, enhanced trial matching, and scalable cohort identification |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials.. The efficacy and safety of rezafungin in invasive candidiasis (IC) and candidaemia was demonstrated in the Phase 2 STRIVE and Phase 3 ReSTORE trials, and an additional cohort of patients in ReSTORE from China (ReSTORE China). This post hoc analysis is the first time tha… |
Clinical Primary efficacy | ORR 50% |
Clinical ORR | 50% |
Clinical Result source | ClinicalTrials.gov NCT00388154 |
Clinical Data Tier / Score | A · 60 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교